Shinhan Investment & Securities decided to 'voluntary compensation' for the victims in Lime reinvestigation

COMPANY / Reporter Kim Jisun / 2023-08-31 03:00:31
 

 

[Alpha Biz=(Chicago) Reporter Kim Jisun] At a time when financial authorities and prosecutors decided to look back into the "Lime scandal," Shinhan Investment & Securities, which sold Lime Fund in the past, suddenly decided to voluntarily compensate the victims.

Shinhan Investment & Securities said on the 30th that it held a board meeting on the 29th and decided to make private reconciliation between Lime Fund and Gen2 Trust, which stopped repurchase. Privateization means that the contracting parties have settled disputes autonomously. Shinhan Investment & Securities also decided to make private reconciliation in December last year for another fund, the Heritage Fund (sales of 390.7 billion won), and returned 100% of the principal to subscribers.

This privateization process regarding the Lime Fund will begin next month. The compensation ratio will apply mutatis mutandis to the criteria for calculating the compensation ratio of the Financial Supervisory Service's dispute settlement committee. Gen2 Trust is worth 418 billion won and Lime's domestic and trade-open funds totaled 144 billion won.

The Financial Supervisory Service has also recently launched an inspection of Mirae Asset Securities, which is known to have sold lime funds to Rep. Kim. The Financial Supervisory Service is intensively looking into why Mirae Asset Securities recommended 16 subscribers of Lime martini Fund No. 4, which Kim joined, about a month before the suspension of the redemption of the Lime Fund.

 

Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)

어플

주요기사

Dongwon F&B Ordered to Revise Unfair Dealer Contract Terms
Coupang Files Lawsuit Challenging Industrial Accident Ruling in Death of Warehouse Worker
Cho Hyun-bum, Chairman of Hankook & Company, Sentence Reduced to Two Years on Embezzlement and Breach of Trust Charges
Korea’s Tax Authority Launches Special Tax Probe into Coupang
Samsung Biologics Acquires GSK’s U.S. Biopharmaceutical Facility to Mitigate Tariff Risks and Expand Production Capacity
뉴스댓글 >

건강이 보이는 대표 K Medical 뉴스

SNS